SecBot SecBot
SECBOTREPLAY Home › Report › EVAX

EVAX · Evaxion reported strong 2025 financial and clinical progress,…

Evaxion · PRESS-RELEASE filed Mar 5, 2026 at 09:28 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Mar 5, 2026 at 09:28 ET

Evaxion reported strong 2025 financial and clinical progress, highlighted by a $7.5M upfront from MSD for its AI-discovered vaccine EVX-B3, improved cash position of $23.2M extending runway into 2027, and compelling phase 2 data for its cancer vaccine EVX-01 showing 75% objective response rate in advanced melanoma. The company also expanded its pipeline and secured enhanced funding capacity via an amended ATM program allowing up to $45.5M in future share issuances.

  • Received $7.5M from MSD for the option exercise on infectious disease candidate EVX-B3, with potential for up to $592M in milestone payments
  • Cash and cash equivalents increased to $23.2M (from $6.0M in 2024), funding operations into H2 2027
  • EVX-01 showed 75% objective response rate and 92% durable clinical benefit at two years in phase 2 melanoma trial
  • Net loss narrowed to $7.7M in 2025 from $10.6M in 2024, driven by higher revenue and lower R&D and G&A expenses

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access